FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016, at 12:30 pm at the St. Regis Hotel in New York, NY.
About Alzheon
Alzheon, Inc. is committed to developing
innovative medicines for patients suffering from Alzheimer’s disease and
other neurological and psychiatric disorders. Our lead clinical
candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule
oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of
Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds
on the safety and efficacy profile of the active compound tramiprosate,
which has been tested in clinical trials involving over 2,000
Alzheimer’s patients. Our mission is to apply our clinical expertise and
technology platform to develop novel therapeutics that make a difference
in patients’ lives by directly addressing the underlying pathology of
devastating neurodegenerative disorders.
For more information, please visit www.alzheon.com.
Contacts
The Yates Network
Media Contact:
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com
